-+ 0.00%
-+ 0.00%
-+ 0.00%

Viking Therapeutics' VK2735 improves BMI category in 74% of patients in 13-week Phase 2 trial

PUBT·11/15/2026 17:07:02
Diffusion vocale
Viking Therapeutics' VK2735 improves BMI category in 74% of patients in 13-week Phase 2 trial
  • Viking Therapeutics presented new results from its Phase 2 VENTURE obesity trial of injectable VK2735 at ObesityWeek 2026.
  • Most treated participants improved their obesity classification over 13 weeks, outperforming placebo; none shifted to a higher BMI category.
  • Participants whose obesity classification improved showed greater reductions in cardiovascular and metabolic risk markers than those whose classification remained unchanged.
  • The ongoing Phase 3 VANQUISH program evaluates weekly injectable VK2735, with trial completion expected in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611151205PR_NEWS_USPR_____LA98030) on November 15, 2026, and is solely responsible for the information contained therein.